Back to Panels

Panel Detail

Locemia Solutions, T1D Exchange, and The Helmsley Charitable Trust: Partnership for development of Dry-Mist Nasal Glucagon

Monday, November 17, 2014
10:15 AM - 10:40 AM
GH - Empire Ballroom I

Millions of people live with diabetes. Severe hypoglycemia (SH) is a potentially fatal complication of diabetes therapy that patients live with on a daily basis. Glucagon, the rescue treatment of choice for SH, is difficult and error-prone to administer, leading to sub-optimal use of an otherwise effective medication, unnecessary delays in treatment, and use of costly medical services. Locemia Solutions, T1D Exchange, and The Helmsley Charitable Trust have partnered to address this unmet medical need and advance a therapy to make rescue of SH as simple as a 'puff in the nose.' Locemia Solutions, with the assistance of these partners, seeks to replace today's antiquated, multiple-step, needle-based, injectable system with Dry-Mist Nasal Glucagon.

Dana Ball, Executive Director and Co-Founder, T1D Exchange; CEO, Unitio
Eliot Brenner, Program Director, Type 1 Diabetes (T1D) Program, The Leona M. and Harry B. Helmsley Charitable Trust
Claude Piche, President & CEO, Locemia Solutions ULC

View the presentation slides as a PDF